Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Nine months ended March 31, 2025 (Q3 2025)
Business Overview: Advanced Biomed is a holding company incorporated in Nevada with principal operations in Taiwan and China. The company focuses on the research and development of microfluidic biochip technologies for precision oncology detection and diagnosis. As of the reporting date, the company has no revenue-generating products and is in the pre-commercial stage, awaiting regulatory approvals for its product candidates (e.g., A+LCGuard, A+Pre, AC-1000).
Recent Milestone: The company completed its Initial Public Offering (IPO) on March 7, 2025, issuing 1,640,000 shares at $4.00 per share.
Key Financial Metrics
| Metric (Nine Months Ended March 31) | 2025 (US$) | 2024 (US$) |
|---|---|---|
| Revenue | 0 | 0 |
| Net Loss | (2,557,358) | (1,972,892) |
| Operating Expenses | (1,808,495) | (1,836,959) |
| Cash and Cash Equivalents (End of Period) | 5,184,100 | 2,663,704 |
| Net Cash Used in Operating Activities | (4,281,093) | (1,650,512) |
| Net Cash Provided by Financing Activities | 6,699,767 | 1,543,284 |
| Total Assets | 8,287,598 | 4,460,247 |
| Total Liabilities | 4,157,815 | 2,796,989 |
| Working Capital | 3,617,805 | 318,650 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 30% to $2.56 million for the nine months ended March 31, 2025, compared to $1.97 million in the prior year period. This increase was primarily driven by a significant foreign exchange loss of approximately $0.74 million due to the revaluation of foreign currency balances.
- Liquidity Improvement: Cash and cash equivalents more than doubled to $5.18 million from $2.66 million, largely due to net IPO proceeds of approximately $5.6 million and related party financing.
- Operating Expenses: Total operating expenses remained relatively flat, decreasing slightly by 2% ($28,464) compared to the prior year. Research and development expenses increased marginally by 1%, while general and administrative expenses decreased by 3%.
- Asset Impairment: The company maintains a full impairment allowance of approximately $1.6 million on acquired patents, reflecting management's assessment that the carrying value may not be recoverable.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that the company's ability to continue as a going concern is dependent on its ability to develop products, obtain regulatory approval, and generate positive operating cash flows. Substantial doubt exists regarding the company's ability to continue as a going concern without additional financing.
- Product Timeline: The company plans to begin clinical research for its lung cancer screening kit (A+LCGuard) by the end of June 2025, with completion anticipated by April 2026. Regulatory approval is expected by October 2027. No revenue is expected until these milestones are met.
- Expansion Plans: The company intends to establish operation centers in North America (California/Washington) and Europe in 2025 to facilitate localized production and registration.
- Risks: Key risks include the failure to obtain regulatory approvals (NMPA, FDA, CE), delays in clinical trials, foreign currency fluctuations, and the inability to secure additional debt or equity financing on acceptable terms.
Investor Verification Checklist
- Regulatory Status: Verify the current status of NMPA registration applications for A+Pre, AC-1000, A+CellScan, and A+LCGuard, as commercialization is entirely dependent on these approvals.
- Cash Burn Rate: Assess the sustainability of the $5.18 million cash balance against the reported operating cash burn of $4.28 million over nine months to determine the runway without further capital raises.
- Related Party Transactions: Review the significant amounts owed to related parties (major stockholders and related corporations), totaling approximately $1.89 million in current liabilities, and the terms of these interest-free loans.
- Asset Valuation: Confirm the rationale for the full impairment of $1.6 million in acquired patents and whether any new intangible assets have been capitalized recently.
- Foreign Exchange Exposure: Evaluate the impact of currency fluctuations (NTD, CNY, HKD) on future financial statements, given the significant foreign exchange loss recorded in the current period.